Forum Replies Created
- Replies
-
-
- February 24, 2014 at 6:25 am
Thanks for all the replies. I've spent the last few hours on http://www.clinicaltrials.gov but couldn't find a study that just showed Dacarbazine vs a placebo, and none that gave response rates by age group. It seems crazy to me that the baseline chemo treatment hasn't been evaluated on its own for efficacy.
I did find some studies that showed Dacarbazine on its own, but as the competitor for other drugs, however no breakdown by age and gender eg:
http://www.clinicaltrials.gov/ct2/show/NCT00110994
Anyone know how to get the detailed results or original published paper?
either way, looking at the studies, it seems that with chemo (Bacarbazine) you are still talking a life expectancy of less than a year. Whilst if there's a response, you can expect to be progression free for a few months, the likelihood of serious adverse events is about 25%, and of other adverse events is high with a broad range of likely side effects.
Is it worth extending life by a few months, only to have those months filled with more medical complications and misery? That's the key question.
-
- February 24, 2014 at 6:25 am
Thanks for all the replies. I've spent the last few hours on http://www.clinicaltrials.gov but couldn't find a study that just showed Dacarbazine vs a placebo, and none that gave response rates by age group. It seems crazy to me that the baseline chemo treatment hasn't been evaluated on its own for efficacy.
I did find some studies that showed Dacarbazine on its own, but as the competitor for other drugs, however no breakdown by age and gender eg:
http://www.clinicaltrials.gov/ct2/show/NCT00110994
Anyone know how to get the detailed results or original published paper?
either way, looking at the studies, it seems that with chemo (Bacarbazine) you are still talking a life expectancy of less than a year. Whilst if there's a response, you can expect to be progression free for a few months, the likelihood of serious adverse events is about 25%, and of other adverse events is high with a broad range of likely side effects.
Is it worth extending life by a few months, only to have those months filled with more medical complications and misery? That's the key question.
-
- February 24, 2014 at 6:25 am
Thanks for all the replies. I've spent the last few hours on http://www.clinicaltrials.gov but couldn't find a study that just showed Dacarbazine vs a placebo, and none that gave response rates by age group. It seems crazy to me that the baseline chemo treatment hasn't been evaluated on its own for efficacy.
I did find some studies that showed Dacarbazine on its own, but as the competitor for other drugs, however no breakdown by age and gender eg:
http://www.clinicaltrials.gov/ct2/show/NCT00110994
Anyone know how to get the detailed results or original published paper?
either way, looking at the studies, it seems that with chemo (Bacarbazine) you are still talking a life expectancy of less than a year. Whilst if there's a response, you can expect to be progression free for a few months, the likelihood of serious adverse events is about 25%, and of other adverse events is high with a broad range of likely side effects.
Is it worth extending life by a few months, only to have those months filled with more medical complications and misery? That's the key question.
-